Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive · Last trade price on Jan 7, 2025

Poseida Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
150.8664.7130.4931.24--
Revenue Growth
203.18%-50.42%317.74%---
Gross Profit
-21.57-92.07-22.41-105.5-103.52-
Operating Income
-62.5-129.5-59.95-141.41-126.55-78.85
Net Income
-60.76-123.43-64-124.97-129.78-86.53
Earnings Per Share
-0.64-1.37-0.89-2.01-3.61-6.86
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash & Investments
230.85212.2282.49206.33309.15125.32
Total Debt
82.7385.4288.7561.261.8231.64
Net Cash (Debt)
148.13126.78193.74145.13247.3493.68
Net Cash Growth
-2.92%-34.56%33.50%-41.32%164.03%728.35%
Net Cash Per Share
1.541.412.692.336.877.42

Cash Flow & CapEx

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Operating Cash Flow
-15.02-92.17-26.77-102.54-113.33-64.52
Capital Expenditures
-2.1-3.07-3.92-2.63-16.91-5.16
Free Cash Flow
-17.13-95.23-30.7-105.18-130.24-69.67
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Gross Margin
-14.30%-142.29%-17.17%---
Operating Margin
-41.43%-200.15%-45.94%-452.69%--
Pretax Margin
-40.25%-190.60%-48.63%-400.07%--
Profit Margin
-40.28%-190.76%-49.05%-400.07%--
FCF Margin
-11.35%-147.18%-23.52%-336.70%--

Valuation

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingAug '26 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
PS Ratio
6.084.973.4913.63--